Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 12, 2005, Pages 1371-1377

  Wielepp, Peter ^a,b   Baller, Detlev ^b   Gleichmann, Ulrich ^b   Pulawski, Ewa ^b   Horstkotte, Dieter ^b   Burchert, Wolfgang ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Atherosclerosis; Coronary artery disease; Hypercholesterolaemia; Lipid lowering drugs; Positron emission tomography

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DILATATION; CORONARY HEMODYNAMICS; CORONARY VASCULAR RESISTANCE; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEART MUSCLE BLOOD FLOW; HUMAN; HYPERCHOLESTEROLEMIA; MALE; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

AGED; BLOOD FLOW VELOCITY; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; CORONARY VESSELS; DISEASE PROGRESSION; EXERCISE TEST; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME; VASODILATION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 28544434187     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1828-6     Document Type: Article

References (39)

1. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51
2. Zeiher A, Drexler H, Wollschläger H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991;84:1984-92
3. Zeiher AM, Krause T, Schächinger V, Minners J, Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 1995;91:2345-52
4. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906
5. Uren NG, Marraccini P, Gistri R, De Silva R, Camici PG. Altered coronary vasodilator reserve and metabolism in myocardium subtended by normal arteries in patients with coronary artery disease. J Am Coll Cardiol 1993;22:650-8
6. Penny WF, Rockman H, Long J, Bhargava V, Carrigan K, Ibriham A, et al. Heterogeneity of vasomotor response to acetylcholine along the human coronary artery. J Am Coll Cardiol 1995;25:1046-55
7. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;3312:488-93
8. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999;99:2871-5
9. Yokohama I, Inoue Y, Moritan T, Ohtomo K, Nagai R. Impaired myocardial vasodilation during hyperaemic stress is improved by simvastatin but not by pravastatin in patients with hypercholesterolemia. Eur Heart J 2004;25:671-9
10. Janatuinen T, Laaksonen R, Vesalainen R, Raitakari O, Lehtimaki T, Nuutila P, et al. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol 2001;38:561-8
11. Campeau L. Grading of angina pectoris. Circulation 1975;54:522-3
12. van den Hoff J, Burchert W. Functional polar maps and 3D visualization. In: Hör G, Krause BJ, Tillmans HH, eds. Cardiological nuclear medicine [in German]. Landsberg, Germany: Ecomed-Verlag, 1997:102-204
13. van den Hoff J, Burchert W, Wolpers HG, Meyer GJ, Hundeshagen H. Visualization and quantification of three- dimensional myocardial wall motion with PET. Eur J Nucl Med 1996;23:1235
14. 11C]Acetate as a quantitative perfusion tracer in myocardial PET. J Nucl Med 2001;42:1174-82
15. Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomography imaging. J Am Coll Cardiol 1990;15:1032-42
16. Imaging guidelines for nuclear cardiology procedures, part 2. American Society of Nuclear Cardiology. J Nucl Cardiol 1999;6:G47-84
17. Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reserve. Circulation 1998;98:1291-6
18. Gewirtz H, Skopicki HA, Abraham SA, Castano H, Dinsmore RE, Alpert NM, et al. Quantitative PET measurements of regional myocardial blood flow: observations in humans with ischemic heart disease. Cardiology 1997;88:62-70
19. Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation 1994;90:808-17
20. Hoffmann JIE. Maximal coronary flow and the concept of coronary vascular reserve. Circulation 1984;70:153-73
21. 2 supply by the DPTI/STTI ratio under maximal coronary dilation. Basic Res Cardiol 1979;74:378-88
22. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission to mography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-8
23. Guethlin M, Kasel AM, Coppenrath K, Ziegler S, Delius W, Schwaiger M. Delayed response ofmyocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 1999;99:475-81
24. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003;23:729-36
25. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-24
26. Böttcher M, Bötker HE, Sonne H, Nielsen TT, Czernin J. Endothelium-dependent and -independent perfusion reserve and the effect of L-arginine on myocardial perfusion in patients with syndrome X. Circulation 1999;99:1795-801
27. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-7
28. Gould KL, Ornish D, Kirkeeide R, Brown S, Stuart Y, Buchi M, et al. Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. Am J Car diol 1992;69:845-53
29. Bassenge E, Heusch G. Endothelial and neuro-humoral control of coronary blood flow in health and disease. Rev Physiol Biochem Pharmacol 1990;116:77-165
30. Gould KL, Ornish D, Scherwitz L, Brown S, Edens RP, Hess MJ, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 1995;274:894-901
31. Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000;342:454-60
32. Buus NH, Bottcher M, Hermansen F, Sander M, Nielsen TT, Mulvany MJ. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 2001;104:2305-10
33. Muzik O, Beanlands R, Hutchins GD, Mangner TJ, Nguyen N, Schwaiger M. Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med 1993;34:83-91
34. Baller D, Wielepp P, Pulawski E, Holzinger J, Weise R, Notohamiprodjo G, et al. Increase and normalization of coronary dilator capacity upon statin therapy in early atherosclerosis assessed with PET (Petichor trial). J Nucl Cardiol 2003;10:S1
35. Sech SM, Montoya JD, Bernier PA, Barnboym E, Brown S, Gregory A, et al. The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. Urology 1998;51:242-50
36. Nees S. Coronary flow increases induced by adenosine and adenine nucleotides are mediated by the coronary endothelium: a new principle of the regulation of coronary flow. Eur Heart J 1989;10 Suppl F:28-35
37. Zanzinger J, Bassenge E. Coronary vasodilation to acetylcholine, adenosine and bradykinin in dogs: effects of inhibition of NO-synthesis and captopril. Eur Heart J 1993;14 Suppl 1:164-8
38. Smits P, Williams SB, Lipson DE, Banitt P, Rongen GA, Creager MA. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation 1995;92:2135-44
39. Campisi R, DiCarli MF. Assessment of coronary flow reserve and microcirculation: a clinical perspective. J Nucl Cardiol 2004;11:3-11